North America Radiopharmaceutical Theranostics Market Forecast to 2028 - Regional Analysis - by Product Type, Radioisotope, Source, Application, Indication, and End User

Description

List of Tables

The North America radiopharmaceutical theranostics market was valued at US$ 795.88 million in 2022 and is expected to reach US$ 1,529.95 million by 2028; it is estimated to register a CAGR of 11.5% from 2022 to 2028.

Rising Application in Treatment of Cardiovascular Disorders

Cardiovascular diseases (CVDs) are among the most prevalent chronic diseases of the 21st century, with a high mortality rate. Due to their sedentary lifestyle, CVDs are the leading cause of mortality and morbidity in developed countries. In addition, obesity and diabetes, and related diseases are associated with cardiovascular disease and are becoming comorbid. In addition, a complication such as coronary artery obstruction is one of the number one causes of death in adults, resulting in thrombus plaque in the intima of the arterial wall, mainly in the carotid artery. Therapeutic applications in cardiovascular diseases include nanomedicine in angina pectoris, myocarditis, myocardial infarction, pericardial disease, thrombosis, atherosclerosis, hyperlipidemia, hypertension, pulmonary arterial hypertension, and stroke. Theranostic nanomedicines can prolong systemic circulation, evade host defense systems, and deliver theranostic agents to the target site for imaging and therapy at the cellular and molecular levels.

As per the 2022 report by the Centers for Disease Control and Prevention (CDC), heart disease is a leading cause of death among men and women in the US. Heart disease was a cause of ~697,000 deaths, i.e., 1 in 5 deaths, in the US in 2020. A National Institute of Health report states that theranostic nanoparticles have gained significant attention in the medical field, as the techniques help overcome complexities and pathophysiological complications associated with CVDs. Cardiovascular imaging of atherosclerosis patients provides pathophysiological evidence that can help treat CVDs. Further, theranostic nanoparticles can be combined with a range of imaging techniques, such as magnetic resonance imaging, positron emission tomography (PET), and computed tomography (CT). Various clinical research studies have been conducted in clinical laboratories so far. A three-in-one therapeutic complex has been constructed, by combining a polymeric photoacoustic probe with nanoparticles-PLCDP@PMH. Clinical in-vivo evaluations reveal that the PLCDP@PMH provides lucrative advantages for the theranostics approach to early-stage atherosclerosis detection in patients.

North America Radiopharmaceutical Theranostics Market Overview

The North America radiopharmaceutical theranostics market is segmented into US, Canada, and Mexico. The US is expected to be among the largest contributors to the radiopharmaceutical theranostics market. The market growth in this region is due to the increasing incidences of chronic diseases, presence of supportive government plans, growing strategic initiatives by the market players, and development of innovative radiotherapies.

North America Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)

North America Radiopharmaceutical Theranostics Market Segmentation

The North America radiopharmaceutical theranostics market is segmented into product type, radioisotope, source, application, indication, end user, and country. Based on product type, the North America radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The PET tracers segment held the largest market share in 2022.

Based on radioisotope, the North America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.

Based on source, the North America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.

Based on application, the North America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.

Based on indication, the North America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.

Based on end user, the North America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.

Based on country, the North America radiopharmaceutical theranostics market is segmented into the US, Canada, and Mexico. The US dominated the North America radiopharmaceutical theranostics market share in 2022.

Bayer AG; GE Healthcare Technologies Inc.; Curium; Lantheus Medical Imaging, Inc.; Telix Pharmaceuticals Ltd.; Cardinal Health Inc.; Advanced Accelerator Applications S.A; Jubilant Radiopharma; Theragnostics; and NuView Life Sciences are the leading companies operating in the North America radiopharmaceutical theranostics market.

Product Code: BMIRE00028187

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 North America Radiopharmaceutical Theranostics Market - by Product Type
- 1.3.2 North America Radiopharmaceutical Theranostics Market - by Radioisotope
- 1.3.3 North America Radiopharmaceutical Theranostics Market - by Source
- 1.3.4 North America Radiopharmaceutical Theranostics Market - by Application
- 1.3.5 North America Radiopharmaceutical Theranostics Market - by Indication
- 1.3.6 North America Radiopharmaceutical Theranostics Market - by End User
- 1.3.7 North America Radiopharmaceutical Theranostics Market - by Country

2. Radiopharmaceutical Theranostics Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Radiopharmaceutical Theranostics Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
4.3 Expert's Opinion

5. North America Radiopharmaceutical Theranostics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Incidence of Cancer
- 5.1.2 Rising Application in Treatment of Cardiovascular Disorders
5.2 Market Restraints
- 5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
5.3 Market Opportunities
- 5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
5.4 Future Trends
- 5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
5.5 Impact Analysis

6. Radiopharmaceutical Theranostics Market - North America Analysis

6.1 North America Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis

7. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type

7.1 Overview
7.2 Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
- 7.2.1 Positron Emission Tomography (PET) Tracers
  - 7.2.1.1 Overview
  - 7.2.1.2 Positron Emission Tomography (PET) Tracers: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.2 Beta Emitters
  - 7.2.2.1 Overview
  - 7.2.2.2 Beta Emitters: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.3 Alpha Emitters
  - 7.2.3.1 Overview
  - 7.2.3.2 Alpha Emitters: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

8. North America Radiopharmaceutical Theranostics Market Analysis - by Radioisotope

8.1 Overview
8.2 Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
- 8.2.1 Technetium-99
  - 8.2.1.1 Overview
  - 8.2.1.2 Technetium-99: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.2 Gallium-68
  - 8.2.2.1 Overview
  - 8.2.2.2 Gallium-68: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.3 Iodine-131
  - 8.2.3.1 Overview
  - 8.2.3.2 Iodine-131: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.4 Iodine-123
  - 8.2.4.1 Overview
  - 8.2.4.2 Iodine-123: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.5 Fluorine-18 (18F)
  - 8.2.5.1 Overview
  - 8.2.5.2 Fluorine-18 (18F): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.6 Yttrium 90 (Y-90)
  - 8.2.6.1 Overview
  - 8.2.6.2 Yttrium 90 (Y-90): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.7 Lutetium (LU) 177
  - 8.2.7.1 Overview
  - 8.2.7.2 Lutetium (LU) 177: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.8 Copper (CU) 67
  - 8.2.8.1 Overview
  - 8.2.8.2 Copper (CU) 67: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.9 Copper (CU) 64
  - 8.2.9.1 Overview
  - 8.2.9.2 Copper (CU) 64: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.10 Others
  - 8.2.10.1 Overview
  - 8.2.10.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

9. North America Radiopharmaceutical Theranostics Market Analysis - by Source

9.1 Overview
9.2 Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
- 9.2.1 Nuclear Reactors
  - 9.2.1.1 Overview
  - 9.2.1.2 Nuclear Reactors: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 9.2.2 Cyclotrons
  - 9.2.2.1 Overview
  - 9.2.2.2 Cyclotrons: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

10. North America Radiopharmaceutical Theranostics Market Analysis - by Application

10.1 Overview
10.2 Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
- 10.2.1 Targeted Therapeutic (Rx)
  - 10.2.1.1 Overview
  - 10.2.1.2 Targeted Therapeutics (Rx): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 10.2.2 Companion Diagnostic (CDx)
  - 10.2.2.1 Overview
  - 10.2.2.2 Companion Diagnostics (CDx): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

11. North America Radiopharmaceutical Theranostics Market Analysis - by Indication

11.1 Overview
11.2 Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
- 11.2.1 Oncology
  - 11.2.1.1 Overview
  - 11.2.1.2 Oncology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.2 Neurology
  - 11.2.2.1 Overview
  - 11.2.2.2 Neurology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.3 Cardiology
  - 11.2.3.1 Overview
  - 11.2.3.2 Cardiology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.4 Others
  - 11.2.4.1 Overview
  - 11.2.4.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

12. North America Radiopharmaceutical Theranostics Market Analysis - by End User

12.1 Overview
12.2 Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
- 12.2.1 Hospitals
  - 12.2.1.1 Overview
  - 12.2.1.2 Hospitals: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.2 Diagnostic Imaging Centers
  - 12.2.2.1 Overview
  - 12.2.2.2 Diagnostic Imaging Centers: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.3 Academic & Research Institutes
  - 12.2.3.1 Overview
  - 12.2.3.2 Academic & Research Institutes: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.4 Others
  - 12.2.4.1 Overview
  - 12.2.4.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

13. North America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Country Analysis

13.1 North America: Radiopharmaceutical Theranostics Market
- 13.1.1 Overview
  - 13.1.1.1 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.1.1.1 Overview
    - 13.1.1.1.2 United States: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.1.1.3 United States Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.1.1.4 United States Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.1.1.5 United States Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.1.1.6 United States Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.1.1.7 United States Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.1.1.8 United States Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.1.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.1.2.1 Overview
    - 13.1.1.2.2 Canada: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.1.2.3 Canada Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.1.2.4 Canada Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.1.2.5 Canada Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.1.2.6 Canada Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.1.2.7 Canada Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.1.2.8 Canada Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.1.3 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.1.3.1 Overview
    - 13.1.1.3.2 Mexico: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.1.3.3 Mexico Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.1.3.4 Mexico Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.1.3.5 Mexico Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.1.3.6 Mexico Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.1.3.7 Mexico Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.1.3.8 Mexico Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)

14. Radiopharmaceutical Theranostics Market - Industry Landscape

14.1 Overview
14.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
14.3 Inorganic Growth Strategies
- 14.3.1 Overview
14.4 Organic Growth Strategies
- 14.4.1 Overview

15. Company Profiles

15.1 Bayer AG
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 GE HealthCare Technologies Inc
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
15.3 Curium
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
15.4 Lantheus Medical Imaging, Inc.
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Products and Services
- 15.4.4 Financial Overview
- 15.4.5 SWOT Analysis
- 15.4.6 Key Developments
15.5 Telix Pharmaceuticals Ltd.
- 15.5.1 Key Facts
- 15.5.2 Business Description
- 15.5.3 Products and Services
- 15.5.4 Financial Overview
- 15.5.5 SWOT Analysis
- 15.5.6 Key Developments
15.6 Cardinal Health Inc
- 15.6.1 Key Facts
- 15.6.2 Business Description
- 15.6.3 Products and Services
- 15.6.4 Financial Overview
- 15.6.5 SWOT Analysis
- 15.6.6 Key Developments
15.7 Advanced Accelerator Applications S.A.
- 15.7.1 Key Facts
- 15.7.2 Business Description
- 15.7.3 Products and Services
- 15.7.4 Financial Overview
- 15.7.5 SWOT Analysis
- 15.7.6 Key Developments
15.8 Jubilant Radiopharma
- 15.8.1 Key Facts
- 15.8.2 Business Description
- 15.8.3 Products and Services
- 15.8.4 Financial Overview
- 15.8.5 SWOT Analysis
- 15.8.6 Key Developments
15.9 Theragnostics
- 15.9.1 Key Facts
- 15.9.2 Business Description
- 15.9.3 Products and Services
- 15.9.4 Financial Overview
- 15.9.5 SWOT Analysis
- 15.9.6 Key Developments
15.10 NuView Life Sciences
- 15.10.1 Key Facts
- 15.10.2 Business Description
- 15.10.3 Products and Services
- 15.10.4 Financial Overview
- 15.10.5 SWOT Analysis
- 15.10.6 Key Developments

16. Appendix

16.1 About The Insight Partners
16.2 Glossary of Terms